Overview
- The FDA cleared a label expansion for Zepbound to be delivered via a four-dose, single-patient KwikPen that covers a full month of therapy.
- Lilly began offering the KwikPen on Feb. 23 to eligible self-pay patients through its LillyDirect platform with starter pricing from $299 per month.
- Patients can choose the new multi-dose pen or existing single-dose vials at the same self-pay price, with availability across six strengths from 2.5 mg to 15 mg.
- Each pen provides four once-weekly injections, leveraging Lilly’s established KwikPen platform also used for Mounjaro and distributed in multiple international regions.
- The rollout supports Lilly’s growing edge over Novo Nordisk, following recent trial results in which Novo’s experimental CagriSema did not match tirzepatide for weight loss.